Emerging Stocks Down Under 24 August 2021: Prescient Therapeutics, COSOL, Cardiex

Emerging Stocks Down Under: Prescient Therapeutics, COSOL, Cardiex

Prescient Therapeutics: Making headway in cancer treatment

In today's edition of Emerging Stocks Down Under, Prescient Therapeutics is a Melbourne-based clinical-stage oncology company currently developing and trialling drugs for the treatment of a variety of cancers. It is currently in Phase-II trials for its lead candidate PTX-200, which has potential to be used for the treatment of HER2-negative breast cancer, amongst other things. Apart from this, the company has a pipeline that targets relapsed and refractory AML, ovarian cancer and cancers with Ras and RhoA mutations.   Also in today's edition, a look at asset-intensive industry software developer COSOL (ASX: COS) and medical device manufacturer Cardiex (ASX: CDX).  

Click here to read the previous edition of Emerging Stocks Down Under published 17 August 2021

For in-depth research reports or to keep up-to-date on the latest Stocks Down Under news see our parent company, Pitt Street Research, or follow us on Facebook and Twitter.

Please register or upgrade your plan to access this content.

Save $$$
30-Day Free Trial
$0
No Credit Card Required!
Get access to 4 publications
Weekly Investor Webinar
Access to Marc & Stuart's Top Picks
Profit Premium
$69
Get access to 4 publications
Access to the full research Archive
Weekly Investor Webinar
Access to Marc & Stuart's Top Picks
30-Day Free Trial
$0
No Credit Card Required!
Get access to 4 publications
Weekly Investor Webinar
Access to Marc & Stuart's Top Picks
Profit Premium
$59
BILLED ANNUALLY
Get access to 4 publications
Access to the full research Archive
Weekly Investor Webinar
Access to Marc & Stuart's Top Picks